Skip to main content

Development of Analytical Method for Levofloxacin, Clarithromycin and Azithromycin in Influent and Secondary Effluent and Their Adverse Effects on Algal Growth

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.

or click here to sign up for a free trial


The pollution of water resources by pharmaceuticals is an emerging public concern in many developed countries. The purpose of this study was to establish an analysis method of antibiotics in secondary effluent and to evaluate its detected concentration from the viewpoint of biological effect. We developed a novel analysis method for levofloxacin (LVFX), clarithromycin (CAM) and azithromycin (AZM) in wastewater using LC/MS/MS, with detection limits of 0.24–4.9 ng/l and recovery ratio of 93–108 %. The concentrations of LVFX, CAM and AZM in the influent of six wastewater treatment plants (WWTPs) that used the activated sludge process were 552, 647 and 260 ng/l, respectively, and in the secondary effluent, 301, 359 and 138 ng/l, respectively. We also evaluated the concentrations of LVFX and CAM in secondary effluents using an algal growth inhibition test. The concentrations of LVFX and CAM in secondary effluents were below their respective no-effect concentrations (NECs). On the other hand, the predicted environmental concentration suggests that the NEC ratio (PEC/PNEC) of CAM would exceed fourteen at the maximum in the secondary effluent if a safety factor of one hundred were set. This suggests a risk of algal growth inhibition due to CAM in WWTP discharge if it is insufficiently diluted in the receiving waters.

Document Type: Research Article


Publication date: January 1, 2005

More about this publication?
  • Proceedings of the Water Environment Federation is an archive of papers published in the proceedings of the annual Water Environment Federation® Technical Exhibition and Conference (WEFTEC® ) and specialty conferences held since the year 2000. These proceedings are not peer reviewed.

    WEF Members: Sign in (right panel) with your IngentaConnect user name and password to receive complimentary access.
  • Subscribe to this Title
  • Membership Information
  • About WEF Proceedings
  • WEFTEC Conference Information
  • Ingenta Connect is not responsible for the content or availability of external websites

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more